All In Biotech

Drug Trial Radar · NCT06622486

First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors

First-in-human Phase 1/2 Trial of EGL-001 in Adult Patients with Selected Advanced And/or Metastatic Solid Tumors

Last checked: Nov 20, 2026Latest source record: Nov 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Sep 27, 2024

Primary completion

Jan 23, 2027

Study completion Jan 23, 2027

Sponsor

Lead sponsor
Egle TherapeuticsIndustry
Sponsor type
Industry
First posted
Oct 2, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This multicenter, open-label, first-in-human, Phase 1/2 study consists of a Part 1 (Phase 1) open-label dose escalation of EGL-001 administered as a single agent and in combination with an anti-PD(L)-1 treatment, followed by a Part 2 (Phase 2) open-label dose expansion of EGL-001 administered at the RP2D in patients with recurrent and/or metastatic solid tumors as monotherapy and/or combination therapy with anti-PD(L)-1.

Conditions

  • Solid Tumor, Adult

Interventions

  • EGL-001Drug

    IV administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the safety, tolerability, dose-limiting toxicities (DLTs) and the maximum tolerated dose (MTD) leading to the recommended Phase 2 doses (RP2Ds)Time frame: Day 1 up to 90 days after last dose
  2. To evaluate the safety, tolerability, dose-limiting toxicities (DLTs) and the maximum tolerated dose (MTD) leading to the recommended Phase 2 doses (RP2Ds)Time frame: Day 1 up to 90 days after last dose
  3. To evaluate the safety, tolerability, dose-limiting toxicities (DLTs) and the maximum tolerated dose (MTD) leading to the recommended Phase 2 doses (RP2Ds)Time frame: Day 1 up to 90 days after last dose
  4. To evaluate the safety, tolerability, dose-limiting toxicities (DLTs) and the maximum tolerated dose (MTD) leading to the recommended Phase 2 doses (RP2Ds)Time frame: Day 1 up to 90 days after last dose

Locations

8 sites in 2 countries. Site status is shown where the registry gives one.

  • Centr Georges Francois Leclerc

    Dijon, France · Not yet recruiting

  • Institut Regional Du Cancer De Montpellier

    Montpellier, France · Recruiting

  • Institut Curie

    Paris, France · Recruiting

  • Institut Gustave Roussy

    Paris, France · Not yet recruiting

  • Hospital Universitari Vall D Hebron

    Barcelona, Spain · Not yet recruiting

  • Hospital Universitario Fundacion Jimenez Diaz

    Madrid, Spain · Not yet recruiting

  • Clinica Universidad De Navarra

    Pamplona, Spain · Not yet recruiting

  • Hospital Clinico Universitario De Valencia

    Valencia, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.